1. Home >
  2. M&A >
  3. Divestiture >
  4. Argentina >
  5. Neovacs Acquires AMEGABIOTECH - Interferon Alpha Manufacturing Technology

M&A Deal Summary

Neovacs Acquires AMEGABIOTECH - Interferon Alpha Manufacturing Technology

On November 15, 2016, Neovacs acquired life science company AMEGABIOTECH - Interferon Alpha Manufacturing Technology from Amega Biotech

Acquisition Highlights
  • This is Neovacs’ 1st transaction in the Life Science sector.
  • This is Neovacs’ 1st transaction in Argentina.

M&A Deal Summary
Date 2016-11-15
Target AMEGABIOTECH - Interferon Alpha Manufacturing Technology
Sector Life Science
Buyer(s) Neovacs
Sellers(s) Amega Biotech
Deal Type Divestiture

Target

AMEGABIOTECH - Interferon Alpha Manufacturing Technology

Argentina
AMEGABIOTECH - Interferon Alpha Manufacturing Technology is a key component of Neovacs’ lead therapeutic candidate, IFNα Kinoid, which is composed of inactivated IFNα coupled with a carrier protein, keyhole limpet hemocyanin.

Search 205,333 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Neovacs

Paris, France
Category Company
Founded 1993
Sector Life Science
Employees18
Revenue 5M EUR (2013)
DESCRIPTION

Neovacs a spin-off from Pierre & Marie Curie University, Paris, France, is a biotechnology company acknowledged as a pioneer in the development of proprietary immunotherapeutics for autoimmune and chronic diseases. Neovacs was founded in 1993 and is based in Paris, France.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Argentina) 1 of 1
Year (2016) 1 of 1

Seller(S) 1

SELLER

Amega Biotech

San Isidro, Argentina
Category Company
Sector Medical Products
DESCRIPTION

Amega Biotech is a developer of of biotech products for human health - located in Argentina. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer. Their work and vision are directed forward.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Argentina) 1 of 1
Year (2016) 1 of 1
Mergr

Product

Company

Legal